Physician profile
Robert S Roth
NPI 1306843883
$12,368.00
in general payments reported to CMS, 2019-2025
48 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,046 · 2020: $1,927 · 2021: $3,321 · 2022: $2,393 · 2023: $2,217 · 2024: $345 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,541 · Education: $94.00 · Debt Forgiveness: $46.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,541.04 |
| Education | $94.00 |
| Debt Forgiveness | $46.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,562.95 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,370.72 | 2019-2024 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $1,370.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $918.14 | 2019-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $761.33 | 2019-2024 | Jardiance, Synjardy |
| Astellas Pharma US INC | $676.75 | 2019-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $660.26 | 2020-2024 | Jardiance, Emgality, Mounjaro |
| Pfizer INC. | $559.24 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $506.28 | 2019-2022 | |
| Glaxosmithkline, LLC. | $372.70 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $352.97 | 2019-2021 | |
| Abbott Laboratories | $321.77 | 2022-2023 | Freestyle Libre 2, Proclaim |
| Amarin Pharma, INC. | $247.49 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $224.52 | 2022 | |
| Esperion Therapeutics, INC. | $203.96 | 2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.